The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 44 | — | 20.1x | Near average | |
Growth | 82 | — | 5.6% | Above average | |
Quality | 5 | -13419.5% | 7.6% | Below average | |
Safety | 58 | 2.0x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
BridgeBio Oncology Therapeutics Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy BridgeBio Oncology Therapeutics Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
BBOT stock shows notable stability in analyst estimates over the past 30 days, with the average price target holding steady at 22 dollars based on a consensus of 6 analysts. The gap between the current price (8.55 dollars) and the lowest price target (18 dollars) reflects significant optimism regarding the company's future despite the absence of current revenue, as analysts focus on narrowing the expected loss per share (EPS) from sharp levels in 2024 to lower levels in late 2025.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.